<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Microglial activation plays a pivotal role in the pathogenesis of various <z:e sem="disease" ids="C0027765" disease_type="Disease or Syndrome" abbrv="">neurologic disorders</z:e>, such as <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e>, and <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Thus, controlling microglial activation is a promising therapeutic strategy for such <z:e sem="disease" ids="C0006111" disease_type="Disease or Syndrome" abbrv="">brain diseases</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, we found that a ginseng saponin metabolite, compound K [20-O-D-glucopyranosyl-20(S)-protopanaxadiol], inhibited the expressions of inducible nitric-<z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase, proinflammatory cytokines, monocyte chemotactic protein-1, matrix metalloproteinase-3, and matrix metalloproteinase-9 in <z:chebi fb="0" ids="16412">lipopolysaccharide</z:chebi> (LPS)-stimulated BV2 microglial cells and primary cultured microglia </plain></SENT>
<SENT sid="3" pm="."><plain>Subsequent mechanistic studies revealed that compound K suppressed microglial activation via inhibiting reactive oxygen species, <z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein kinases, and nuclear factor-κB/activator protein-1 activities with enhancement of <z:chebi fb="4" ids="30413">heme</z:chebi> oxygenase-1/<z:chebi fb="11" ids="22586">antioxidant</z:chebi> response element signaling </plain></SENT>
<SENT sid="4" pm="."><plain>To address the anti-inflammatory effects of compound K in vivo, we used two <z:e sem="disease" ids="C0006111" disease_type="Disease or Syndrome" abbrv="">brain disease</z:e> models of mice: <z:hpo ids='HP_0100806'>sepsis</z:hpo> (systemic <z:mp ids='MP_0001845'>inflammation</z:mp>) and <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Compound K reduced the number of Iba1-positive activated microglia and inhibited the expressions of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-α and interleukin-1β in the LPS-induced <z:hpo ids='HP_0100806'>sepsis</z:hpo> brain </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, compound K reduced the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume of ischemic brain induced by middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> and suppressed microglial activation in the ischemic cortex </plain></SENT>
<SENT sid="7" pm="."><plain>The results collectively suggest that compound K is a promising agent for prevention and/or treatment of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> and other neuroinflammatory disorders </plain></SENT>
</text></document>